Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL38700

ELVUCITABINE
🧪 Phase II
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
🧪 Phase II
Nc1nc(=O)n([C@@H]2C=C[C@H](CO)O2)cc1F
ChEMBL ↗ Properties Compare Identifier

Basic Information

ChEMBL ID CHEMBL38700
Name ELVUCITABINE
Phase Phase II
Structure Type MOL
InChI Key HSBKFSPNDWWPSL-VDTYLAMSSA-N

Known Names

.beta.-l-fd4c ACH-126,443 ACH-126443 Beta-l-fd4c Elvucitabina Elvucitabine L-fd4c
12
Targets
20
Activities
2
Assay Types
30
PK Parameters
20
Publications
7
Known Names
2
Indications
2
Mechanisms

Molecular Properties

227.2
MW (Da)
-0.59
ALogP
6
HBA
2
HBD
90.4
PSA (Ų)
0.66
QED
0
Ro5 Violations
2
Rot. Bonds

Drug Information

Molecule Type Small molecule
Chirality Single Enantiomer
USAN Stem -citabine
USAN Year 2003

Extended Properties

Molecular Formula C9H10FN3O3
MW 227.19
Aromatic Rings 1
Heavy Atoms 16
NP-Likeness 0.69

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Human immunodeficiency virus type 1 reverse transcriptase inhibitor INHIBITOR Human immunodeficiency virus type 1 reverse transcriptase ✓ ✓
DNA polymerase/reverse transcriptase inhibitor INHIBITOR DNA polymerase/reverse transcriptase ✓ ✓

Indications

Hepatitis B, Chronic HIV Infections

Activity Summary

IC50 11 meas. best 6.34
EC50 9 meas. best 8.1

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
Hepatitis B virus
CHEMBL613497
 EC50 8.1 8.1 8.0 2
HepG2
CHEMBL395
 EC50 7.77 7.77 17.0 1
Human immunodeficiency virus 1
CHEMBL378
 EC50 7.47 7.47 34.0 1
ADMET
CHEMBL612558
 EC50 7.17 7.17 67.0 1
Human immunodeficiency virus
CHEMBL613758
 EC50 7.0 6.85 100.0 2
Human immunodeficiency virus type 1 reverse transcriptase
CHEMBL247
 EC50 6.85 6.8 140.0 2
CCRF-CEM
CHEMBL382
 IC50 6.34 5.26 460.0 4
MT2
CHEMBL614184
 IC50 5.05 5.05 9000.0 1
Vero
CHEMBL391
 IC50 5.03 5.03 9400.0 1
ADMET
CHEMBL612558
 IC50 4.89 4.89 12900.0 1
LNCaP
CHEMBL612518
 IC50 4.26 4.26 55200.0 1
MCF7
CHEMBL387
 IC50 4.08 4.08 82800.0 1
SK-MES-1
CHEMBL614923
 IC50 4.0 4.0 99100.0 1

Pharmacokinetic Data

Parameter Value Units Species
AUC 732.0 ng.hr.mL-1 Homo sapiens
AUC 1029.0 ng.hr.mL-1 Homo sapiens
AUC 1243.0 ng.hr.mL-1 Homo sapiens
AUC 568.0 ng.hr.mL-1 Homo sapiens
AUC 790.0 ng.hr.mL-1 Homo sapiens
AUC 979.3 ng.hr.mL-1 Homo sapiens
AUC 59.9 ng.hr.mL-1 Homo sapiens
AUC 155.0 ng.hr.mL-1 Homo sapiens
AUC 262.0 ng.hr.mL-1 Homo sapiens
AUC 214.0 ng.hr.mL-1 Homo sapiens
AUC 435.0 ng.hr.mL-1 Homo sapiens
AUC 749.0 ng.hr.mL-1 Homo sapiens
CL 17.6 L/hr Homo sapiens
CL 28.0 L/hr Homo sapiens
Cmax 599.06 nM Homo sapiens
Cmax 450.28 nM Homo sapiens
Cmax 31.91 nM Homo sapiens
Cmax 111.36 nM Homo sapiens
Cmax 172.1 nM Homo sapiens
Cmax 101.68 nM Homo sapiens
Cmax 219.64 nM Homo sapiens
Cmax 475.37 nM Homo sapiens
F 55.4 % Homo sapiens
ka 0.183 /hr Homo sapiens
ka 0.127 /hr Homo sapiens
ka 0.459 /hr Homo sapiens
ka 0.483 /hr Homo sapiens
ka 0.065 /hr Homo sapiens
ka 0.42 /hr Homo sapiens
T1/2 0.75 hr -

Activity Data Samples

Top measurements by pChEMBL value

Target Type Rel. Value Units pChEMBL Assay PubMed
Hepatitis B virus EC50 = 8.0 nM 8.1 In vitro inhibitory activity against proliferation of HBV viral cell 9873711
Hepatitis B virus EC50 = 8.0 nM 8.1 Compound concentration required to inhibit the viral cell proliferation by 50% a... 9873396
HepG2 EC50 = 17.0 nM 7.77 Tested for effective concentration against HBV treated with drug every 3 days fo... 9871628
Human immunodeficiency virus 1 EC50 = 34.0 nM 7.47 Tested in vitro for anti HIV-1 activity against PBM cells 10072683
ADMET EC50 = 67.0 nM 7.17 The anti-HIV-1 activity was assayed in activated human peripheral blood mononucl... 15081000
Human immunodeficiency virus EC50 = 100.0 nM 7.0 Compound concentration required to inhibit the viral cell proliferation by 50% a... 9873396
Human immunodeficiency virus type 1 reverse transcriptase EC50 = 140.0 nM 6.85 In vitro antiviral activity against HIV-1 Reverse transcriptase M184V mutant 12781181
Human immunodeficiency virus type 1 reverse transcriptase EC50 = 180.0 nM 6.75 In vitro antiviral activity against HIV-1 Reverse transcriptase wild type 12781181
Human immunodeficiency virus EC50 = 200.0 nM 6.7 In vitro inhibitory activity against proliferation of HIV viral cell 9873711
CCRF-CEM IC50 = 460.0 nM 6.34 Tested in vitro for anticancer activity against CEM cells 10072683
CCRF-CEM IC50 = 6500.0 nM 5.19 In vitro inhibitory activity against growth of HIV infected CEM cell line 9873711
MT2 IC50 = 9000.0 nM 5.05 In vitro inhibitory activity against growth of HIV infected MT-2/IIIB cell line 9873711
Vero IC50 = 9400.0 nM 5.03 Tested in vitro for cytotoxicity against Vero cells 10072683
ADMET IC50 = 12900.0 nM 4.89 Tested in vitro for cytotoxicity against PBM cells 10072683
CCRF-CEM IC50 = 13000.0 nM 4.89 Tested for cytotoxicity in human T-cell lymphoblastic leukemia cell line (CEM) 9871628
CCRF-CEM IC50 = 24000.0 nM 4.62 In vitro inhibitory activity against growth of HIV infected CEM cells combined w... 9873711
LNCaP IC50 = 55200.0 nM 4.26 Tested in vitro for anticancer activity against LNCaP cells 10072683
MCF7 IC50 = 82800.0 nM 4.08 Tested in vitro for anticancer activity against MCF-7 cells 10072683
SK-MES-1 IC50 = 99100.0 nM 4.0 Tested in vitro for anticancer activity against SK-MES-1 cells 10072683

Literature References

PubMed DOI Target Context # Activities
19015343 10.1128/aac.00907-08 Homo sapiens 38
19015353 10.1128/aac.00905-08 Homo sapiens 34
9871628 10.1016/s0960-894x(97)10178-0 HepG2 4
15081000 10.1016/j.bmcl.2004.02.031 ADMET 4
9873711 10.1016/s0960-894x(98)00599-x CCRF-CEM 2
8627596 10.1021/jm950836q HepG2 2
10072683 10.1021/jm980510s Human immunodeficiency virus 1 2
- 10.6019/CHEMBL4651402 SARS-CoV-2 2
8627596 10.1021/jm950836q CCRF-CEM 2
19015343 10.1128/aac.00907-08 Plasma 2
12781181 10.1016/s0960-894x(03)00330-5 Human immunodeficiency virus type 1 reverse transcriptase 2
10072683 10.1021/jm980510s SK-MEL-28 1
15081000 10.1016/j.bmcl.2004.02.031 Vero 1
10072683 10.1021/jm980510s LNCaP 1
10072683 10.1021/jm980510s MCF7 1
10072683 10.1021/jm980510s SK-MES-1 1
10072683 10.1021/jm980510s HepG2 1
10072683 10.1021/jm980510s CCRF-CEM 1
10072683 10.1021/jm980510s ADMET 1
9873396 10.1016/s0960-894x(98)00277-7 CCRF-CEM 1

Data from ChEMBL 36 via Core Engine